Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paltusotine in Carcinoid Syndrome (Phase 2 Safety, PK, and Dose Response Study)
2022-000762-18Phase 2Active
- Sponsor
- Crinetics Pharmaceuticals
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of paltusotine in Carcinoid Syndrome (CS) (3 arms), sponsored by Crinetics Pharmaceuticals. Primary endpoint: Safety and tolerability of paltusotine. Started Nov 2022; status: active.
02
Drugs
paltusotine
03
Conditions
Carcinoid Syndrome (CS)
Beyond the preview
Go deeper on 2022-000762-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000762-18.